Free Daily Podcast Summary
The Bio Report: Daily Summaries Delivered
by Levine Media Group
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 days ago37 min
Rewriting the Rules of Antibody Drug Design
Most marketed antibodies work as antagonists, simply shutting off a receptor, even though many immune, metabolic, and cancer pathways require more nuanced control. Metaphore Biotechnologies' function‑first platform combines live-cell experiments with machine learning to read how receptors and binding partners behave in living systems, distill those complex dynamics into the key functional features, and then design functional antibodies that agonize, bias, or multi-target pathways from the outset. Metaphore CEO Angela Hwang discusses how the company is using this approach to open up difficult or previously undruggable targets, generate medicines with better profiles, and give drug developers greater control over complex signaling than traditional drug development approaches allow.
- 1 weeks ago30 min
Mapping Cellular Stress Biology to Tackle Undruggable Targets
Cells continuously sense their environment and in response to stressors, adapt, recover, or die. Soley Therapeutics uses its AI platform to capture thousands of intracellular features and map how cells sense, interpret, and respond to stress. The approach gives Soley the ability to pursue previously undruggable targets. It has generated more than 10 novel oncology programs in less than two years and advanced two first‑in‑class experimental small molecule therapies toward the clinic. Yerem Yeghiazarians, co-founder and CEO of Soley, discusses the science behind the company’s first-in-class lead candidate, the applicability of Soley’s platform to a broad set of diseases, and the capital efficiency of the company’s approach to drug development.
- 2 weeks ago30 min
Turning Abandoned Drugs into Breakthroughs
Promising drugs can become abandoned or underused because of tolerability issues, poor drug‑like properties, or other fixable limitations, even when there is already compelling human evidence that they work. PureTech Health starts with an unmet need and human pharmacology, then systematically dissects and solves the specific liabilities of discontinued drugs to unlock breakthroughs in an approach that has proved to be a highly efficient means of value creation. Eric Elenko, president and co‑founder of PureTech, discusses the company’s disciplined approach to drug innovation around rescuing promising but discontinued therapeutics, its hub‑and‑spoke structure, and how this model can neutralize emotional bias, enforce clear success criteria, and turn partially derisked assets into commercial successes.
- 3 weeks ago45 min
Targeting Cancer Survival Genes in Solid Tumors
Most cancer therapies hit one or a few pathways that tumors can escape by mutating, activating alternative survival routes, or pumping drugs out, leading to relapse and poor survival in indications such as liver, ovarian, and prostate cancer. Nuago is developing single-construct short RNAs that simultaneously silence many survival genes in cancer cells to achieve durable tumor cell killing with minimal toxicity to normal tissue. Nuago CEO Robert Schickel discusses the biology behind toxic RNA seeds and tumor-suppressive microRNAs; the company’s lead programs in liver, ovarian, and prostate cancer; and the implications if its cancer-agnostic RNA platform can live up to its preclinical promise.
- May 6, 202636 min
Addressing Treatment Gaps in Gout
Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source of silent suffering for millions of people who are often blamed for their disease rather than offered effective care. Current therapies to lower urate levels suffer from limitations and safety challenges. Crystalys Therapeutics is in late-stage development of a next‑generation urate inhibitor that is already approved in Japan and China. Crystalys CEO James Mackay discusses the biology of gout, why standard therapies often fail to get uric acid to target levels, and how the company’s next‑generation URAT1 inhibitor may fill the treatment gap and change daily life for patients living with moderate to severe gout.
- Apr 29, 202628 min
An Off-the-Shelf Cell Therapy to Calm Cytokine Storms
Small molecule drugs and monoclonal antibodies often fall short at addressing severe inflammatory and immune‑mediated diseases. Mesoblast has spent more than 15 years industrializing mesenchymal stromal cell therapies to treat these conditions. In late 2024, it won U.S. Food and Drug Administration approval for Ryoncil, the first mesenchymal stromal cell therapy approved in the United States. Ryoncil is approved to treat steroid‑refractory acute graft‑versus‑host disease in pediatric patients 2 months of age and older. Mesoblast founder and CEO Silviu Itescu discusses how this class of therapy can help dampen cytokine‑driven hyperinflammation, how the company is extending its platform into other high‑burden conditions, and what distinguishes its second‑generation cell therapy now in development from its first.
- Apr 22, 202629 min
Slowing Disability in MS
Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop the slow neurodegeneration that drives long-term disability, especially in progressive forms of the disease. Immunic Therapeutics is trying to reshape the treatment landscape for multiple sclerosis with its experimental once-daily oral therapy, designed not only to curb inflammation and relapses but also to tackle the neurodegeneration that silently drives disability progression in both relapsing and progressive forms of MS. Daniel Vitt, CEO of Immunic, discusses how the company’s experimental MS therapy works, how it may protect neurons from cell death, and the potential for its dual mechanism of action to change the treatment landscape.
- Apr 15, 202635 min
Tuning, Rather than Blocking, Immunity in IBD
The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection risks, and drive high treatment cycling. Abivax is betting that fine-tuning, rather than suppressing, the immune system can reshape the treatment paradigm in IBD. Marc de Garidel, CEO of Abivax, discusses how a once-failed HIV candidate evolved into a late‑stage oral IBD therapy that may deliver durable remission, how it acts upstream of key inflammatory pathways, and its potential in a crowded but still underserved IBD market.
Get The Bio Report summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Biohack-it
A weekly exploration of biohacking, holistic health, and science-driven strategies for optimizing physical and mental well-being.
Huberman Lab
Explores neuroscience and science-based tools for understanding and optimizing brain function, behavior, and health.
Nature Podcast
Weekly science stories from Nature journal, covering research across all fields with insights from scientists and editors.
Drug Story
Each episode explores the unexpected stories behind prescription drugs and the business of treating illness.
LifeBlood
Experts discuss wellbeing and personal growth to help listeners improve their lives and align with their desired lifestyle.
The Empowering Neurologist Podcast
Explores health and wellness through interviews with leading experts in the field.
ZOE Science & Nutrition
Experts break down cutting-edge health and nutrition science to help you make better choices for your body and gut.
The Dr. Gabrielle Lyon Show
Discusses health, longevity, and mental resilience through science-based conversations with medical and wellness experts.
Wellness, Actually with Emily Oster & Perry Wilson, MD
Two experts analyze health news, debunk wellness myths, and answer listener questions using data and medical evidence.
Radiolab
Explores complex questions through investigative journalism, blending science, history, and human stories with innovative sound design.
Plenary Session
Discusses medicine, oncology, and health policy with expert guests and critical analysis.
Unbiased Science
Two scientists analyze health topics using objective, evidence-based approaches to inform everyday decisions.
About The Bio Report
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Bio Report in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Bio Report daily summary?
It's a free AI-powered email that summarizes new episodes of The Bio Report as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Bio Report podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Bio Report product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Levine Media Group.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Bio Report release new episodes?
The Bio Report publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Bio Report cover?
The Bio Report covers topics including Science, Business, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Bio Report summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.